Skip to main content
. 2016 Jun 27;15(2):135–145. doi: 10.1038/cmi.2016.33

Figure 4.

Figure 4

Immunization with AdCEA576–669HSP70L1-DCs protects mice from CEA-positive tumor challenge in vivo. (a–e) Lymphatic and splenic cells from HLA-A2.1/H-2 kb mice immunization with DCs, CEA576–669HSP70L1-DCs (CH-DC), AdCtrl-DCs (AdCtrl-DC) or AdCEA576–669HSP70L1-DCs (AdCH-DC) (106/mice) from the same strain of mice were evaluated for the frequencies of CEA-specific CTLs by HLA-A2/CAP1 pentamer staining and FACS analysis (a), or were adaptively transferred into SW480 or LS-174 T-loaded nude mice (5 × 106/mice) every other week for three times after 1 week of injection of tumor cells, and then the tumor growth (b, c, all n=6 mice/group) and survival (d, e, all n=8 mice/group) of mice were monitored at indicated time. Representative results of three (a) or two (b–e) independent experiments are shown. ***P<0.001; **P<0.01 compared with DC or AdCtrl-DC; *P<0.05. Two-way ANOVA (b, c) or log-rank (Mantel–Cox) test (d, e). ANOVA, analysis of variance; CAP1, CEA peptide-1; CEA, carcinoembryonic antigen; FACS, fluorescence-activated cell sorting.